1. Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia.
- Author
-
Dolan S, Christofides A, Doucette S, and Shafey M
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Canada, Clinical Trials as Topic, Humans, Medical Oncology organization & administration, Medical Oncology trends, Protein Kinase Inhibitors adverse effects, Societies, Medical, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Congresses as Topic, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Medical Oncology methods, Protein Kinase Inhibitors administration & dosage
- Abstract
Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually, 29-30 May. At the meeting, results from key studies about the treatment of chronic lymphocytic leukemia (cll) were disseminated. Studies examined the efficacy and safety of ibrutinib, acalabrutinib, zanubrutinib, and venetoclax as monotherapy or in combination with novel agents for patients with treatment-naïve and relapsed or refractory cll. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice., Competing Interests: CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: SD was a primary investigator for the ascend and elevate-tn studies, funded by AstraZeneca. AC and SD received funding from AstraZeneca for the development of this document. MS has received honoraria from AstraZeneca, Janssen, AbbVie, Roche, Gilead, and Bristol–Myers Squibb. MS is also involved in clinical trials with AstraZeneca, AbbVie, Roche, and Bristol Myers Squibb., (2020 Multimed Inc.)
- Published
- 2020
- Full Text
- View/download PDF